quinazolines has been researched along with Stroke in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 11 (84.62) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Chung, JI; Jalin, AMA; Jin, S; Joung, C; Ju, C; Kim, BS; Kim, WK; Lee, KS; Lee, S; Pahk, K; Ryu, JM; Song, HY | 1 |
| Broniscer, A; Merchant, TE; Nguyen, R; Onar-Thomas, A; Patay, Z; Pierson, CR | 1 |
| Kuznetsova, PI; Melikyan, AL; Raskurazhev, AA; Subortseva, IN; Tanashyan, MM | 1 |
| Shannon, RP | 1 |
| Darsalia, V; Klein, T; Larsson, M; Mansouri, S; Nathanson, D; Nyström, T; Olverling, A; Patrone, C; Sjöholm, Å | 1 |
| Hunter, L; Jones, NM; Lizarme, Y; Marcolin, GM; Morris, JC; Wangsahardja, J | 1 |
| Bae, E; Chen, CT; Kuan, HH; Shia, KS; Song, JS; Wang, Y; Wu, CH; Wu, KJ; Yeh, KC; Yu, SJ | 1 |
| Vetter, C | 1 |
| Durand, JB; Kim, P; Yusuf, SW | 1 |
| Brea, J; Cadavid, MI; Campillo, NE; Ceballos, P; Gil, C; Loza, MI; Martínez, A; Moro, MA; Pérez, C; Pérez, DI; Perez-Castillo, A; Redondo, M; Val, C; Zarruk, JG | 1 |
| Johansen, OE; Neubacher, D; Patel, S; von Eynatten, M; Woerle, HJ | 1 |
| Furberg, CD; Moore, TJ | 1 |
| Darlöf, E; Darsalia, V; Klein, T; Nyström, T; Olverling, A; Ortsäter, H; Patrone, C; Sjöholm, Å; Wolbert, P | 1 |
1 review(s) available for quinazolines and Stroke
| Article | Year |
|---|---|
Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme.
Topics: Aged; Angina, Unstable; Biomarkers; Blood Glucose; Cardiovascular Diseases; Clinical Trials, Phase III as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Evidence-Based Medicine; Female; Glycated Hemoglobin; Hospitalization; Humans; Linagliptin; Male; Middle Aged; Myocardial Infarction; Patient Safety; Proportional Hazards Models; Prospective Studies; Purines; Quinazolines; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Stroke; Treatment Outcome | 2012 |
1 trial(s) available for quinazolines and Stroke
| Article | Year |
|---|---|
Treatment-Related Noncontiguous Radiologic Changes in Children With Diffuse Intrinsic Pontine Glioma Treated With Expanded Irradiation Fields and Antiangiogenic Therapy.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Brain; Brain Stem Neoplasms; Child; Child, Preschool; Combined Modality Therapy; Dasatinib; Disease-Free Survival; Female; Glioma; Humans; Leukoencephalopathies; Magnetic Resonance Imaging; Male; Piperidines; Quinazolines; Radiotherapy, Conformal; Stroke; Tumor Burden | 2017 |
11 other study(ies) available for quinazolines and Stroke
| Article | Year |
|---|---|
The Quinazoline Otaplimastat (SP-8203) Reduces the Hemorrhagic Transformation and Mortality Aggravated after Delayed rtPA-Induced Thrombolysis in Cerebral Ischemia.
Topics: Acetamides; Animals; Brain Ischemia; Cerebral Hemorrhage; Disease Models, Animal; Endothelial Cells; Fibrinolytic Agents; Humans; Infarction, Middle Cerebral Artery; Ischemic Stroke; Male; Matrix Metalloproteinases; Quinazolines; Quinazolinones; Rats; Rats, Sprague-Dawley; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator | 2022 |
Acute ischemic stroke in the setting of essential thrombocytemia (clinical cases).
Topics: Brain Ischemia; Cerebrovascular Circulation; Female; Gene Frequency; Humans; Janus Kinase 2; Middle Aged; Platelet Aggregation Inhibitors; Platelet Count; Quinazolines; Stroke; Thrombocythemia, Essential; Treatment Outcome | 2018 |
DPP-4 inhibition and neuroprotection: do mechanisms matter?
Topics: Animals; Diabetes Mellitus, Experimental; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |
Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.
Topics: Animals; Cell Proliferation; Cell Survival; Cells, Cultured; Diabetes Mellitus, Type 2; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Mice; Mice, Inbred C57BL; Neural Stem Cells; Purines; Quinazolines; Stroke; Structure-Activity Relationship | 2014 |
Synthesis and neuroprotective activity of dictyoquinazol A and analogues.
Topics: Cell Death; Cell Survival; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neuroprotective Agents; Quinazolines; Stroke; Structure-Activity Relationship; Tumor Cells, Cultured | 2016 |
A Novel CXCR4 Antagonist CX549 Induces Neuroprotection in Stroke Brain.
Topics: Animals; Anti-Inflammatory Agents; Behavior, Animal; Benzylamines; Brain; Brain Infarction; Chemotaxis; Cyclams; HEK293 Cells; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cells; Heterocyclic Compounds; Humans; Interleukin-6; Male; Mice, Inbred C57BL; Neurons; Neuroprotection; Neuroprotective Agents; Quinazolines; Rats, Sprague-Dawley; Receptors, CXCR4; Stroke; Triazoles; Tumor Necrosis Factor-alpha | 2017 |
[Migraine can signal a risk for heart and brain].
Topics: Azepines; Calcitonin Gene-Related Peptide Receptor Antagonists; Dipeptides; Female; Humans; Imidazoles; Migraine Disorders; Migraine with Aura; Myocardial Infarction; Piperazines; Quinazolines; Risk Factors; Stroke; Tryptamines | 2009 |
Erlotinib or gefitinib for non-small-cell lung cancer.
Topics: Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Myocardial Ischemia; Protein Kinase Inhibitors; Quinazolines; Stroke | 2011 |
Neuroprotective efficacy of quinazoline type phosphodiesterase 7 inhibitors in cellular cultures and experimental stroke model.
Topics: Animals; Blood-Brain Barrier; Cells, Cultured; Cyclic Nucleotide Phosphodiesterases, Type 7; Disease Models, Animal; Enzyme Inhibitors; Infarction, Middle Cerebral Artery; Male; Mice; Neuroprotective Agents; Permeability; Quinazolines; Stroke | 2012 |
The safety risks of innovation: the FDA's Expedited Drug Development Pathway.
Topics: Anticoagulants; Antineoplastic Agents; Benzimidazoles; beta-Alanine; Carcinoma, Neuroendocrine; Clinical Trials as Topic; Dabigatran; Drug Approval; Efficiency, Organizational; Fingolimod Hydrochloride; Humans; Immunosuppressive Agents; Multiple Sclerosis; Patient Safety; Piperidines; Propylene Glycols; Quinazolines; Risk; Sphingosine; Stroke; Thyroid Neoplasms; Time Factors; United States; United States Food and Drug Administration | 2012 |
The DPP-4 inhibitor linagliptin counteracts stroke in the normal and diabetic mouse brain: a comparison with glimepiride.
Topics: Animals; Diabetes Mellitus, Experimental; Dietary Fats; Dipeptidyl-Peptidase IV Inhibitors; Hypoglycemic Agents; Linagliptin; Male; Mice; Obesity; Purines; Quinazolines; Stroke; Sulfonylurea Compounds | 2013 |